



Authorised Use

The Ministry of Public Health in State of Qatar (MOPH) has issued a Conditional Registration Approval for PAXLOVID for the treatment of COVID 19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID 19.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

The patient information leaflet linked to the QR Code on the product pack has the latest updated product information approved in your country, which may be more up to date than the paper leaflet.

[Read the PAXLOVID™ Package
Leaflet: Information for the Patient](#)



[نشرة العبوة: معلومات للمريض](#)

